Charles Schwab Investment Management Inc. Raises Stock Position in Pediatrix Medical Group, Inc. $MD

Charles Schwab Investment Management Inc. increased its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 7.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,552,585 shares of the company’s stock after purchasing an additional 105,345 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.81% of Pediatrix Medical Group worth $33,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Ieq Capital LLC raised its holdings in shares of Pediatrix Medical Group by 37.0% during the fourth quarter. Ieq Capital LLC now owns 59,535 shares of the company’s stock worth $1,273,000 after purchasing an additional 16,079 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Pediatrix Medical Group by 0.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,956 shares of the company’s stock valued at $5,133,000 after buying an additional 1,651 shares during the period. Wells Fargo & Company MN grew its position in Pediatrix Medical Group by 52.0% during the fourth quarter. Wells Fargo & Company MN now owns 120,163 shares of the company’s stock valued at $2,570,000 after buying an additional 41,108 shares during the period. Lord Abbett & CO. LLC acquired a new stake in Pediatrix Medical Group during the fourth quarter valued at $5,298,000. Finally, Castleark Management LLC acquired a new stake in Pediatrix Medical Group during the fourth quarter valued at $3,403,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on MD shares. Jefferies Financial Group restated a “buy” rating and set a $27.00 price target on shares of Pediatrix Medical Group in a research report on Monday, April 20th. Truist Financial raised their price target on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, April 13th. Deutsche Bank Aktiengesellschaft set a $19.00 price target on shares of Pediatrix Medical Group in a research report on Friday, February 20th. Zacks Research lowered shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 23rd. Finally, Mizuho set a $24.00 price target on shares of Pediatrix Medical Group in a research report on Friday, May 8th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $22.50.

Insider Activity

In other news, Director Shirley A. Weis sold 36,028 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.80% of the company’s stock.

Pediatrix Medical Group Stock Performance

NYSE:MD opened at $22.43 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 10.89 and a beta of 0.70. The company’s 50-day moving average is $21.54 and its two-hundred day moving average is $21.56. Pediatrix Medical Group, Inc. has a 1-year low of $11.84 and a 1-year high of $24.99.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $476.20 million for the quarter, compared to the consensus estimate of $465.83 million. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The business’s revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.33 EPS. Analysts forecast that Pediatrix Medical Group, Inc. will post 2.08 EPS for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.